Protein C deficiency

For patient information click here

Protein C deficiency
ICD-9	289.81
OMIM	176860
DiseasesDB	10807
MedlinePlus	000559
MeSH	D020151

WikiDoc Resources for Protein C deficiency
Articles
Most recent articles on Protein C deficiency Most cited articles on Protein C deficiency Review articles on Protein C deficiency Articles on Protein C deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Protein C deficiency Images of Protein C deficiency Photos of Protein C deficiency Podcasts & MP3s on Protein C deficiency Videos on Protein C deficiency
Evidence Based Medicine
Cochrane Collaboration on Protein C deficiency Bandolier on Protein C deficiency TRIP on Protein C deficiency
Clinical Trials
Ongoing Trials on Protein C deficiency at Clinical Trials.gov Trial results on Protein C deficiency Clinical Trials on Protein C deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Protein C deficiency NICE Guidance on Protein C deficiency NHS PRODIGY Guidance FDA on Protein C deficiency CDC on Protein C deficiency
Books
Books on Protein C deficiency
News
Protein C deficiency in the news Be alerted to news on Protein C deficiency News trends on Protein C deficiency
Commentary
Blogs on Protein C deficiency
Definitions
Definitions of Protein C deficiency
Patient Resources / Community
Patient resources on Protein C deficiency Discussion groups on Protein C deficiency Patient Handouts on Protein C deficiency Directions to Hospitals Treating Protein C deficiency Risk calculators and risk factors for Protein C deficiency
Healthcare Provider Resources
Symptoms of Protein C deficiency Causes & Risk Factors for Protein C deficiency Diagnostic studies for Protein C deficiency Treatment of Protein C deficiency
Continuing Medical Education (CME)
CME Programs on Protein C deficiency
International
Protein C deficiency en Espanol Protein C deficiency en Francais
Business
Protein C deficiency in the Marketplace Patents on Protein C deficiency
Experimental / Informatics
List of terms related to Protein C deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Protein C deficiency is a rare genetic trait that predisposes to thrombotic disease. It was first described in 1981. The disease belongs to a group of genetic disorders know as thrombophilias.
The prevalence of protein C deficiency has been estimated to about 0,2% of the general population.

Protein C deficiency is associated with an increased incidence of venous thromboembolism (relative risk 7), whereas no association with arterial thrombotic disease has been found.

Pathophysiology

The main function of protein C is its anticoagulant property as an inhibitor of coagulation factors V and VIII. There are two main types of protein C mutations that lead to protein C deficiency:

• Type I: Quantitative defects of protein C (low production or short protein halflife)
• Type II: Qualitative defects, in which interaction with other molecules is abnormal. Defects in interaction with thrombomodulin, phospholipids, factors V/VIII and others have been described.

Homozygous protein C mutations often causes a severe thrombotic disorder known as purpura fulminans.proteinc defiency has only had 16 caes before 1999

Treatment

Primary phrophylaxis with aspirin, heparin or warfarin should be considered in known familial cases.
Anticoagulant prophylaxis is given to all who develop a venous clot regardless of underlying cause. Studies have demonstrated an increased risk of recurrent venours thromboembolic events in patients with protein C deficiency. Therefore, long-term anticoagulation therapy with warfarin should be considered in these patients.

Homozygous protein C defect constitutes a potentially life-threatening disease, and warrants the use of supplemental protein C concentrates.